What is the appropriate third‑line therapy for a 58‑year‑old fit patient with follicular lymphoma who relapsed 5 years after first‑line rituximab‑cyclophosphamide‑doxorubicin‑vincristine‑prednisone (R‑CHOP) and second‑line rituximab plus lenalidomide (R2) in the INMIND study, without histologic transformation?

Third-Line Therapy for Late-Relapsing Follicular Lymphoma

For this 58-year-old fit patient with late relapse (5 years) after R-CHOP and R2, CD19-directed CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel) or CD3×CD20 bispecific antibodies (mosunetuzumab or epcoritamab) represent the most appropriate third-line options, with CAR T-cell therapy showing superior durability outcomes in recent analyses. 1

Rationale for Treatment Selection

The 2025 NCCN Guidelines establish that after ≥2 prior systemic therapies for relapsed/refractory FL, approved options include CD19-directed CAR T-cell therapies and CD3×CD20 bispecific antibodies 1. Since this patient received R2 as second-line therapy (which is now standard after the AUGMENT trial), they have exhausted the lenalidomide-based approach and require a mechanistically distinct therapy.

Key Clinical Context

This patient's 5-year remission after first-line R-CHOP indicates a late relapse rather than early progression. This is prognostically favorable compared to progression of disease within 24 months (POD24), which carries poor survival outcomes 1. The ESMO 2021 guidelines specifically recommend non-chemotherapy approaches for later relapses 2.

Treatment Algorithm for Third-Line Selection

Primary Recommendation: CAR T-Cell Therapy

Preferred agents:

• Axicabtagene ciloleucel (axi-cel)
• Tisagenlecleucel (tisa-cel)
• Lisocabtagene maraleucel (liso-cel)

Supporting evidence:

• 24-month PFS: 62-65% with CAR T vs 44-49% with bispecific antibodies 3, 4
• Complete response rates: 82% with CAR T vs 67% with bispecific antibodies 3
• 3-year PFS: 54% with CAR T vs 42% with bispecific antibodies 3
• Restricted mean survival time at 24 months: 18.6-19.5 months for CAR T vs 14.8-16.2 months for bispecific antibodies 4

Patient eligibility criteria:

• Age 58 and fit status: excellent candidate
• No histologic transformation confirmed
• Adequate organ function required
• Proximity to CAR T center and caregiver support during first 30 days critical 5

Alternative: CD3×CD20 Bispecific Antibodies

If CAR T unavailable or patient preference:

• Mosunetuzumab (preferred based on data maturity)
• Epcoritamab

Advantages:

• Off-the-shelf availability (no manufacturing delay)
• Outpatient administration possible
• Lower rate of severe neurotoxicity (0% grade ≥3 ICANS vs 8% with CAR T) 3

Disadvantages:

• Lower durability: 24-month PFS 43-49% vs 62-65% with CAR T 3, 4
• Higher infection rates: 17% grade ≥3 vs 9% with CAR T 3
• Requires prolonged treatment duration

Third Option: Zanubrutinib + Obinutuzumab

Consider if:

• Patient declines cellular therapy
• Logistical barriers to CAR T or bispecific antibodies
• Preference for oral therapy component

Performance:

• 24-month PFS: 54% 4
• 12-month PFS: 62% 4
• Intermediate durability between CAR T and bispecific antibodies

Critical Pitfalls to Avoid

1. Do NOT repeat lenalidomide-based therapy: Patient already received R2 in second line; repeating would be inappropriate 1

2. Do NOT use conventional chemoimmunotherapy: ESMO guidelines explicitly recommend non-chemotherapy approaches for later relapses 2

3. Must confirm no histologic transformation: Obtain new biopsy before initiating therapy, as transformation would alter treatment approach 2

4. Avoid autologous stem cell transplant in this setting: ASCT is reserved for patients with brief first remissions (<12-24 months), not applicable here 2

Toxicity Considerations

CAR T-cell therapy:

• Grade ≥3 cytokine release syndrome: manageable with tocilizumab
• Grade ≥3 ICANS: 8% (higher than bispecific antibodies) 3
• 1-year non-relapse mortality: 3% 3
• Requires inpatient monitoring during peak toxicity window (days 1-14)

Bispecific antibodies:

• Grade ≥3 infections: 17% (requires antimicrobial prophylaxis) 3
• Cytokine release syndrome: primarily with first doses, manageable outpatient
• No severe ICANS reported 3
• Prolonged immunosuppression with extended treatment

Sequencing Considerations

Given this patient's late relapse and fit status, CAR T-cell therapy should be prioritized to maximize durability of response and potentially extend time to next treatment 3, 5, 4. The superior 24-month PFS (62-65% vs 44-49%) and complete response rates (82% vs 67%) translate to meaningful clinical benefit in quality of life through longer treatment-free intervals.

If CAR T is pursued and eventually fails, bispecific antibodies or BTK inhibitor combinations remain available as subsequent options. Conversely, if bispecific antibodies are used first and fail, CAR T remains viable but the patient will have received one additional line of therapy, potentially affecting CAR T eligibility or performance.

The 2025 NCCN Guidelines support both approaches as Category 1 evidence 1, but recent meta-analyses demonstrate CAR T's superior durability profile in this exact clinical scenario 3, 4.